Compare Pfizer with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs NATCO PHARMA - Comparison Results

PFIZER     Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER NATCO PHARMA PFIZER/
NATCO PHARMA
 
P/E (TTM) x 37.3 20.6 181.3% View Chart
P/BV x 6.4 3.2 196.7% View Chart
Dividend Yield % 0.5 1.0 51.5%  

Financials

 PFIZER   NATCO PHARMA
EQUITY SHARE DATA
    PFIZER
Mar-19
NATCO PHARMA
Mar-19
PFIZER/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs3,840849 452.3%   
Low Rs2,080557 373.4%   
Sales per share (Unadj.) Rs455.0573.8 79.3%  
Earnings per share (Unadj.) Rs93.8176.0 53.3%  
Cash flow per share (Unadj.) Rs109.4198.2 55.2%  
Dividends per share (Unadj.) Rs22.506.25 360.0%  
Dividend yield (eoy) %0.80.9 85.5%  
Book value per share (Unadj.) Rs658.2842.7 78.1%  
Shares outstanding (eoy) m45.7536.50 125.3%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x6.51.2 531.1%   
Avg P/E ratio x31.64.0 790.2%  
P/CF ratio (eoy) x27.13.5 762.9%  
Price / Book Value ratio x4.50.8 539.1%  
Dividend payout %24.03.6 675.6%   
Avg Mkt Cap Rs m135,42025,660 527.8%   
No. of employees `0002.65.0 53.1%   
Total wages/salary Rs m3,2383,559 91.0%   
Avg. sales/employee Rs Th7,911.44,225.3 187.2%   
Avg. wages/employee Rs Th1,230.9718.0 171.4%   
Avg. net profit/employee Rs Th1,630.71,295.9 125.8%   
INCOME DATA
Net Sales Rs m20,81520,945 99.4%  
Other income Rs m1,6741,302 128.6%   
Total revenues Rs m22,48922,247 101.1%   
Gross profit Rs m5,7127,948 71.9%  
Depreciation Rs m714810 88.1%   
Interest Rs m73193 37.8%   
Profit before tax Rs m6,5998,247 80.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,3091,823 126.6%   
Profit after tax Rs m4,2916,424 66.8%  
Gross profit margin %27.437.9 72.3%  
Effective tax rate %35.022.1 158.3%   
Net profit margin %20.630.7 67.2%  
BALANCE SHEET DATA
Current assets Rs m27,16723,472 115.7%   
Current liabilities Rs m8,9177,287 122.4%   
Net working cap to sales %87.777.3 113.5%  
Current ratio x3.03.2 94.6%  
Inventory Days Days6892 73.5%  
Debtors Days Days3088 34.1%  
Net fixed assets Rs m8,86218,648 47.5%   
Share capital Rs m458365 125.3%   
"Free" reserves Rs m29,65634,525 85.9%   
Net worth Rs m30,11330,760 97.9%   
Long term debt Rs m250-   
Total assets Rs m39,40043,031 91.6%  
Interest coverage x91.543.7 209.3%   
Debt to equity ratio x00-  
Sales to assets ratio x0.50.5 108.5%   
Return on assets %11.115.4 72.0%  
Return on equity %14.220.9 68.2%  
Return on capital %22.127.4 80.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m42811,536 3.7%   
Fx outflow Rs m7862,939 26.8%   
Net fx Rs m-3588,597 -4.2%   
CASH FLOW
From Operations Rs m9786,688 14.6%  
From Investments Rs m351-6,122 -5.7%  
From Financial Activity Rs m-1,099-509 215.8%  
Net Cashflow Rs m23166 349.7%  

Share Holding

Indian Promoters % 0.0 52.0 -  
Foreign collaborators % 63.9 1.5 4,346.9%  
Indian inst/Mut Fund % 7.5 7.8 95.7%  
FIIs % 4.9 16.6 29.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 26.0 91.2%  
Shareholders   85,207 25,395 335.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   ALEMBIC PHARMA  DISHMAN PHARMA  TTK HEALTHCARE  ASTRAZENECA PHARMA  BIOCON   

Compare PFIZER With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

How to Trade this Market Crash(Podcast)

India's #1 trader, Vijay Bhambwani, decodes the crash...and reveals hidden opportunities one could profit from.

Related Views on News

PFIZER Announces Quarterly Results (3QFY20); Net Profit Up 5.4% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, PFIZER has posted a net profit of Rs 1 bn (up 5.4% YoY). Sales on the other hand came in at Rs 5 bn (up 4.7% YoY). Read on for a complete analysis of PFIZER's quarterly results.

NATCO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 34.5% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 34.5% YoY). Sales on the other hand came in at Rs 5 bn (down 13.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

PFIZER Announces Quarterly Results (2QFY20); Net Profit Up 61.0% (Quarterly Result Update)

Oct 29, 2019 | Updated on Oct 29, 2019

For the quarter ended September 2019, PFIZER has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 6 bn (up 9.1% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (1QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PFIZER has posted a net profit of Rs 1 bn (up 22.8% YoY). Sales on the other hand came in at Rs 5 bn (up 6.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

More Views on News

Most Popular

Multibaggers of the Next Decade(The 5 Minute Wrapup)

Feb 26, 2020

The one key ingredient to be seen amongst top multibaggers of the next decade.

The Next Few Days Are Crucial for Smallcap Investors - And 3 Must-Buy Stocks(Profit Hunter)

Feb 19, 2020

While I have been writing about the rebound in smallcaps for quite some time now... I have shied from the question - When exactly is the smallcap rebound happening. Well, the answer is now.

The Top 8 Trading Mistakes You Should Avoid(Fast Profits Daily)

Feb 18, 2020

Avoid these mistakes and your trading will turn much more profitable.

Corona Virus Could Trigger a Rally in this Stock(Profit Hunter)

Feb 20, 2020

A company which benefits from crude oil and coronavirus - if you would like to know more about it read this.

Why I Expect the Coronavirus to Benefit My Latest Trade Recommendation(Fast Profits Daily)

Feb 19, 2020

This is how my latest trade recommendation will benefit from the Coronavirus scare.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get our special report, Secret to Increasing Your Trading Profits Today Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Feb 28, 2020 (Close)

TRACK PFIZER

COMPARE PFIZER WITH

MARKET STATS